Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Investigation of the acid-base and electromigration properties of 5-azacytosine derivatives using capillary electrophoresis and density functional theory calculations.

Geffertová D, Ali ST, Šolínová V, Krečmerová M, Holý A, Havlas Z, Kašička V.

J Chromatogr A. 2017 Jan 6;1479:185-193. doi: 10.1016/j.chroma.2016.11.058. Epub 2016 Nov 29.

PMID:
27919519
2.

Estimation of apparent binding constant of complexes of selected acyclic nucleoside phosphonates with β-cyclodextrin by affinity capillary electrophoresis.

Šolínová V, Mikysková H, Kaiser MM, Janeba Z, Holý A, Kašička V.

Electrophoresis. 2016 Jan;37(2):239-47. doi: 10.1002/elps.201500337. Epub 2015 Nov 6.

PMID:
26426398
3.
4.

Accidental contamination of a German town's drinking water with sodium hydroxide.

Lendowski L, Färber H, Holy A, Darius A, Ehrich B, Wippermann C, Küfner B, Exner M.

Int J Hyg Environ Health. 2015 May;218(3):366-9. doi: 10.1016/j.ijheh.2015.01.006. Epub 2015 Feb 3.

PMID:
25687345
5.

Fracture strength of root filled premolar teeth restored with silorane and methacrylate-based resin composite.

Taha NA, Maghaireh GA, Bagheri R, Abu Holy A.

J Dent. 2015 Jun;43(6):735-41. doi: 10.1016/j.jdent.2015.01.011. Epub 2015 Feb 3.

PMID:
25656772
6.

A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.

Balzarini J, Andrei G, Balestra E, Huskens D, Vanpouille C, Introini A, Zicari S, Liekens S, Snoeck R, Holý A, Perno CF, Margolis L, Schols D.

PLoS Pathog. 2013;9(7):e1003456. doi: 10.1371/journal.ppat.1003456. Epub 2013 Jul 25.

7.

The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.

Baszczyňski O, Hocková D, Janeba Z, Holý A, Jansa P, Dračínský M, Keough DT, Guddat LW.

Eur J Med Chem. 2013 Sep;67:81-9. doi: 10.1016/j.ejmech.2013.06.032. Epub 2013 Jun 22.

PMID:
23850568
8.

Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.

Procházková E, Jansa P, Březinová A, Cechová L, Mertlíková-Kaiserová H, Holý A, Dračínský M.

Bioorg Med Chem Lett. 2012 Oct 15;22(20):6405-9. doi: 10.1016/j.bmcl.2012.08.065. Epub 2012 Aug 28.

PMID:
22989530
10.

An enzymatic glycosylation of nucleoside analogues using β-galactosidase from Escherichia coli.

Blažek J, Jansa P, Baszczyňski O, Kaiser MM, Otmar M, Krečmerová M, Drančínský M, Holý A, Králová B.

Bioorg Med Chem. 2012 May 1;20(9):3111-8. doi: 10.1016/j.bmc.2012.02.062. Epub 2012 Mar 15.

PMID:
22465858
11.

Antiviral effect of HPMPC (Cidofovir®), entrapped in cationic liposomes: in vitro study on MDBK cell and BHV-1 virus.

Korvasová Z, Drašar L, Mašek J, Turánek Knotigová P, Kulich P, Matiašovic J, Kovařčík K, Bartheldyová E, Koudelka Š, Škrabalová M, Miller AD, Holý A, Ledvina M, Turánek J.

J Control Release. 2012 Jun 10;160(2):330-8. doi: 10.1016/j.jconrel.2012.01.040. Epub 2012 Feb 2.

PMID:
22326403
12.

Involvement of MAP kinases in the cytotoxicity of acyclic nucleoside phosphonates.

Mertlíková-Kaiserová H, Nejedlá M, Holy A, Votruba I.

Anticancer Res. 2012 Feb;32(2):497-501. Erratum in: Anticancer Res. 2012 Mar;32(3):1117.

PMID:
22287737
13.

Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.

Krečmerová M, Dračínský M, Hocková D, Holý A, Keough DT, Guddat LW.

Bioorg Med Chem. 2012 Feb 1;20(3):1222-30. doi: 10.1016/j.bmc.2011.12.034. Epub 2011 Dec 30.

PMID:
22249123
14.

Differential effects of acyclic nucleoside phosphonates on nitric oxide and cytokines in rat hepatocytes and macrophages.

Kostecká P, Holý A, Farghali H, Zídek Z, Kmoníčková E.

Int Immunopharmacol. 2012 Feb;12(2):342-9. doi: 10.1016/j.intimp.2011.12.005. Epub 2011 Dec 21.

PMID:
22198073
15.

Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.

Česnek M, Hocková D, Holý A, Dračínský M, Baszczyňski O, Jersey Jd, Keough DT, Guddat LW.

Bioorg Med Chem. 2012 Jan 15;20(2):1076-89. doi: 10.1016/j.bmc.2011.11.034. Epub 2011 Dec 1.

PMID:
22178188
16.

Determination of the antioxidative activity of substituted 5-aminopyrimidines.

Procházková E, Jansa P, Dračínský M, Holý A, Mertlíková-Kaiserová H.

Free Radic Res. 2012 Jan;46(1):61-7. doi: 10.3109/10715762.2011.638292. Epub 2011 Nov 28.

PMID:
22059896
17.

Antiviral activity of tenofovir against Cauliflower mosaic virus and its metabolism in Brassica pekinensis plants.

Spak J, Votruba I, Pavingerová D, Holý A, Spaková V, Petrzik K.

Antiviral Res. 2011 Nov;92(2):378-81. doi: 10.1016/j.antiviral.2011.08.014. Epub 2011 Aug 26.

PMID:
21889541
18.

Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity.

Hocková D, Holý A, Andrei G, Snoeck R, Balzarini J.

Bioorg Med Chem. 2011 Aug 1;19(15):4445-53. doi: 10.1016/j.bmc.2011.06.045. Epub 2011 Jun 22.

PMID:
21745746
19.

Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr-PMEDAP.

Vávrová K, Kovaříková P, Skolová B, Líbalová M, Roh J, Cáp R, Holý A, Hrabálek A.

Pharm Res. 2011 Dec;28(12):3105-15. doi: 10.1007/s11095-011-0508-4. Epub 2011 Jun 14.

PMID:
21671133
20.

A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities.

Jansa P, Baszczyňski O, Dračínský M, Votruba I, Zídek Z, Bahador G, Stepan G, Cihlar T, Mackman R, Holý A, Janeba Z.

Eur J Med Chem. 2011 Sep;46(9):3748-54. doi: 10.1016/j.ejmech.2011.05.040. Epub 2011 May 23.

PMID:
21664011
21.

6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs.

de Jersey J, Holý A, Hocková D, Naesens L, Keough DT, Guddat LW.

Curr Top Med Chem. 2011;11(16):2085-102. Review.

PMID:
21619515
22.

New prodrugs of Adefovir and Cidofovir.

Tichý T, Andrei G, Dračínský M, Holý A, Balzarini J, Snoeck R, Krečmerová M.

Bioorg Med Chem. 2011 Jun 1;19(11):3527-39. doi: 10.1016/j.bmc.2011.04.016. Epub 2011 Apr 22.

PMID:
21565516
23.

Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG.

Mertlíková-Kaiserová H, Rumlová M, Tloušťová E, Procházková E, Holý A, Votruba I.

Biochem Pharmacol. 2011 Jul 15;82(2):131-8. doi: 10.1016/j.bcp.2011.04.002. Epub 2011 Apr 14.

PMID:
21515241
24.

Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.

Baszczyňski O, Jansa P, Dračínský M, Klepetářová B, Holý A, Votruba I, de Clercq E, Balzarini J, Janeba Z.

Bioorg Med Chem. 2011 Apr 1;19(7):2114-24. doi: 10.1016/j.bmc.2011.02.050. Epub 2011 Mar 4.

PMID:
21429755
25.

Inhibition of SAH-hydrolase activity during seed germination leads to deregulation of flowering genes and altered flower morphology in tobacco.

Fulneček J, Matyášek R, Votruba I, Holý A, Křížová K, Kovařík A.

Mol Genet Genomics. 2011 Mar;285(3):225-36. doi: 10.1007/s00438-011-0601-8. Epub 2011 Jan 28.

PMID:
21274566
26.

New in vitro method for evaluating antiviral activity of acyclic nucleoside phosphonates against plant viruses.

Spak J, Holý A, Pavingerová D, Votruba I, Spaková V, Petrzik K.

Antiviral Res. 2010 Dec;88(3):296-303. doi: 10.1016/j.antiviral.2010.09.019. Epub 2010 Oct 7.

PMID:
20933018
27.

Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.

Krecmerová M, Holý A, Andrei G, Pomeisl K, Tichý T, Brehová P, Masojídková M, Dracínský M, Pohl R, Laflamme G, Naesens L, Hui H, Cihlar T, Neyts J, De Clercq E, Balzarini J, Snoeck R.

J Med Chem. 2010 Oct 14;53(19):6825-37. doi: 10.1021/jm901828c.

PMID:
20809641
28.

Role of caspases and CD95/Fas in the apoptotic effects of a nucleotide analog PMEG in CCRF-CEM cells.

Mertlíková-Kaiserová H, Votruba I, Matousová M, Holy A, Hájek M.

Anticancer Res. 2010 Jul;30(7):2791-8.

PMID:
20683014
29.

Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP.

Hájek M, Cvilink V, Votruba I, Holý A, Mertlíková-Kaiserová H.

Eur J Pharmacol. 2010 Sep 15;643(1):6-12. doi: 10.1016/j.ejphar.2010.06.006. Epub 2010 Jun 22.

PMID:
20599933
30.

Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy.

Keough DT, Hocková D, Krecmerová M, Cesnek M, Holý A, Naesens L, Brereton IM, Winzor DJ, de Jersey J, Guddat LW.

Mol Biochem Parasitol. 2010 Oct;173(2):165-9. doi: 10.1016/j.molbiopara.2010.05.018. Epub 2010 Jun 1.

PMID:
20595032
31.

Design, synthesis, and biological evaluation of novel coxsackievirus B3 inhibitors.

Sála M, De Palma AM, Hrebabecký H, Nencka R, Dracínský M, Leyssen P, Neyts J, Holý A.

Bioorg Med Chem. 2010 Jun 15;18(12):4374-84. doi: 10.1016/j.bmc.2010.04.081. Epub 2010 Apr 29.

PMID:
20576576
32.
33.

The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization.

Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J.

J Biol Chem. 2010 Apr 16;285(16):12101-8. doi: 10.1074/jbc.M109.096529. Epub 2010 Feb 17.

34.

Acyclic nucleoside phosphonates with 5-azacytosine base moiety substituted in C-6 position.

Krecmerová M, Masojídková M, Holý A.

Bioorg Med Chem. 2010 Jan 1;18(1):387-95. doi: 10.1016/j.bmc.2009.10.044. Epub 2009 Oct 29.

PMID:
19914075
35.

Czech bibliometric system fosters mediocre research.

Konvalinka J, Illnerová H, Hobza P, Horejsí V, Holý A, Jungwirth P, Paces V, Martásek P, Zlatuska J.

Nature. 2009 Aug 27;460(7259):1079. doi: 10.1038/4601079c. No abstract available.

PMID:
19713911
36.

Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Hocková D, Holý A, Masojídková M, Keough DT, de Jersey J, Guddat LW.

Bioorg Med Chem. 2009 Sep 1;17(17):6218-32. doi: 10.1016/j.bmc.2009.07.044. Epub 2009 Jul 25.

PMID:
19666228
37.
38.

Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.

Keough DT, Hocková D, Holý A, Naesens LM, Skinner-Adams TS, Jersey Jd, Guddat LW.

J Med Chem. 2009 Jul 23;52(14):4391-9. doi: 10.1021/jm900267n.

PMID:
19527031
39.

In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates PMEDAP and PMEG.

Otová B, Hrdy J, Votruba I, Holy A.

Anticancer Res. 2009 Apr;29(4):1295-302.

40.

Enzymatic polymerization of phosphonate nucleosides.

Renders M, Lievrouw R, Krecmerová M, Holý A, Herdewijn P.

Chembiochem. 2008 Nov 24;9(17):2883-8. doi: 10.1002/cbic.200800494.

PMID:
19006151
41.

Modulation of cell cycle progression and of antibody production in mouse hybridomas by a nucleotide analogue.

Franek F, Holý A, Votruba I, Eckschlager T.

Cytotechnology. 1998 Nov;28(1-3):65-72. doi: 10.1023/A:1008017328061.

42.

Acyclic nucleoside bisphosphonates: synthesis and properties of chiral 2-amino-4,6-bis[(phosphonomethoxy)alkoxy]pyrimidines.

Doláková P, Dracínský M, Masojídková M, Solínová V, Kasicka V, Holý A.

Eur J Med Chem. 2009 Jun;44(6):2408-24. doi: 10.1016/j.ejmech.2008.09.031. Epub 2008 Oct 2.

43.

[Acyclic nucleoside phosphonates as potential antineoplastic agents].

Votruba I, Otová B, Holý A.

Cas Lek Cesk. 2008;147(9):471-7. Review. Czech.

PMID:
18988489
44.

Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Gammon DB, Snoeck R, Fiten P, Krecmerová M, Holý A, De Clercq E, Opdenakker G, Evans DH, Andrei G.

J Virol. 2008 Dec;82(24):12520-34. doi: 10.1128/JVI.01528-08. Epub 2008 Oct 8.

45.
46.

Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine.

Naesens L, Andrei G, Votruba I, Krecmerová M, Holý A, Neyts J, De Clercq E, Snoeck R.

Biochem Pharmacol. 2008 Oct 15;76(8):997-1005. doi: 10.1016/j.bcp.2008.08.009. Epub 2008 Aug 19.

PMID:
18773877
47.

Permeation enhancer dodecyl 6-(dimethylamino)hexanoate increases transdermal and topical delivery of adefovir: influence of pH, ion-pairing and skin species.

Vávrová K, Lorencová K, Novotný J, Holý A, Hrabálek A.

Eur J Pharm Biopharm. 2008 Nov;70(3):901-7. doi: 10.1016/j.ejpb.2008.07.002. Epub 2008 Jul 15.

PMID:
18675907
48.

Study of chemical stability of antivirally active 5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopy.

Dracínský M, Krecmerová M, Holý A.

Bioorg Med Chem. 2008 Jul 15;16(14):6778-82. doi: 10.1016/j.bmc.2008.05.058. Epub 2008 Jun 12.

PMID:
18554916
49.

Ternary Copper(II) Complexes in Solution Formed With 8-Aza Derivatives of the Antiviral Nucleotide Analogue 9-[2-(Phosphonomethoxy)Ethyl]Adenine (PMEA).

Gómez-Coca RB, Kapinos LE, Holý A, Vilaplana RA, González-Vílchez F, Sigel H.

Met Based Drugs. 2000;7(6):313-24. doi: 10.1155/MBD.2000.313.

50.

Synthesis of acyclic nucleoside phosphonates.

Holý A.

Curr Protoc Nucleic Acid Chem. 2005 Oct;Chapter 14:Unit 14.2. doi: 10.1002/0471142700.nc1402s22.

PMID:
18428938

Supplemental Content

Support Center